Monoclonal antibodies against laryngeal carcinomas. Preliminary report

Following types of monoclonal antibodies (MoAb) (HMFG 1, 2 and AI 16.9) were used in twenty patients with laryngeal carcinomas (10 pharyngolaryngeal carcinomas, T4 N+ MO, and 10 vestibulo-glottic carcinomas, T1 T2, N+ N-, MO). The demonstration of MoAb's binding was performed with immunoperoxidase technique. The results demonstrate that the HMFG 1 and 2 antibodies fixed to both T and N, mostly good or very good, while the AI 16.9 antibody fixed in a various way. None of these three MoAb's was specific for the tissue of metastasis-free satellite lymph nodes.